Case 1:22-cv-00252-MSG Document 211-7 Filed 02/02/24 Page 1 of 4 PageID #: 14435
`Case 1:22-cv-00252-MSG Document 211-7 Filed 02/02/24 Page 1 of 4 PagelD #: 14435
`
`EXHIBIT C
`EXHIBIT C
`
`

`

`Case 1:22-cv-00252-MSG Document 211-7 Filed 02/02/24 Page 2 of 4 PageID #: 14436
`
`Moderna's Search Terms, Sources, Dates, and Hits
`End Date Custodians Non-Custodial Hits + Fam.
`Moderna's Search Terms
`Start Date
`(LNP OR (lipid W/1 nanoparticle*)) W/5 (mRNA OR messenger RNA)
`2/28/2012 2/28/2022
`8
`Sharepoint
`107,168
`((LNP OR (lipid W/1 nanoparticle*)) W/3 (mRNA OR messenger RNA)) AND (ratio* OR
`(lipid W/2 molar) OR (lipid W/2 content*) OR (lipid W/2 concentration*) OR (lipid W/2
`conc) OR (lipid W/2 conc.) OR "##mol \u0025" OR "##mol\u0025" OR licens* OR
`agreement OR sublicense OR sublicens* OR sub-licens*)
`
`N/A
`
`17,564
`
`2/28/2012 2/28/2022
`
`HB
`
`#
`I-01
`I-01.1
`
`I-02
`I-03
`
`I-04
`I-05
`I-06
`I-07
`
`I-08
`
`I-09
`
`I-10
`
`I-11
`I-12
`
`I-13
`I-14
`
`I-15
`
`I-16
`
`I-17
`
`I-18
`
`I-19
`
`8 + AT
`8 + AT
`8 + AT
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT
`
`2/28/2012 2/28/2022
`(LNP OR (lipid W/1 nanoparticle*)) W/5 siRNA
`(SM-102 OR SM102 OR SM-000102) W/15 (mRNA-1273 OR Spikevax* OR Elasomeran*) 2/28/2016 2/28/2022
`
`8 + AT
`8 + AT
`
`(SM-102 OR SM102 OR SM-000102) W/10 PEG*
`(SM-102 OR SM102 OR SM-000102) W/10 cholesterol
`(SM-102 OR SM102 OR SM-000102) W/10 DSPC
`(SM-102 OR SM102 OR SM-000102) W/15 "##mol\u0025"
`
`2/28/2016 2/28/2022
`2/28/2016 2/28/2022
`2/28/2016 2/28/2022
`2/28/2016 2/28/2022
`
`(SM-102 OR SM102 OR SM-000102) W/15 (molar ratio OR lipid ratio OR ratio of lipids)
`
`2/28/2016 2/28/2022
`
`(SM-102 OR SM102 OR SM-000102) W/15 (lipid W/2 ratio)
`
`(SM-102 OR SM102 OR SM-000102) W/10 (stability OR (tissue W/2 clearance) OR
`(mRNA W/2 delivery))
`(SM-102 OR SM102 OR SM-000102) W/3 (mRNA OR messenger RNA)
`(SM-102 OR SM102 OR SM-000102) W/7 (LNP OR (lipid W/1 nanoparticle*))
`
`(SM-102 OR SM102 OR SM-000102) W/10 (MC3 OR DLin-MC3-DMA)
`(MC3 OR DLin-MC3-DMA) W/5 ((plasmid W/2 DNA) OR siRNA OR mRNA)
`
`(entrap* OR encapsulat*) W/3 (assay* OR test* OR stud* OR efficienc* OR rate OR
`percent*)
`fully W/3 encapsulat*
`
`(Inex OR Protiva OR Genevant OR Tekmira OR Arbutus) W/10 (lipid OR LNP OR mRNA
`OR siRNA OR ratio* OR patent* OR (intellectual W/1 propert*) OR IP OR licens* OR
`agreement OR sublicense* OR sub-licens*)
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`2/28/2016 2/28/2022
`
`8
`8 + AT
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2012 2/28/2022
`
`8 + AT
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`
`Sharepoint
`Sharepoint
`Sharepoint
`Sharepoint
`Sharepoint
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`Sharepoint
`Sharepoint
`Sharepoint
`
`9,590
`12,899
`
`34,634
`23,293
`28,360
`7,605
`
`1,471
`
`3,409
`
`11,995
`
`22,806
`33,962
`
`21,796
`
`Sharepoint
`
`29,372
`
`33,472
`
`616
`
`3,840
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`2/28/2012 2/28/2022
`
`Sharepoint
`
`7,149
`
`(Acuitas OR AlCana OR Alnylam) W/5 (lipid OR LNP OR mRNA OR siRNA OR ratio* OR
`patent* OR (intellectual W/1 propert*) OR IP OR licens* OR agreement OR sublicens*
`OR sub-licens*)
`((cation* OR ioniz*) W/2 lipid) W/5 (mRNA OR siRNA)
`
`lipid W/10 (licens* OR agreement OR sublicense OR sublicens* OR sub-licens*)
`
`(LNP OR (lipid W/1 nanoparticle*)) W/10 (licens* OR agreement OR sublicense OR
`sublicens* OR sub-licens*)
`(*.gov OR *.mil) AND (52-227* OR “authorization and consent”) AND (COVID* OR SARS-
`CoV-2 OR “mRNA-1273”)
`(*.gov OR *.mil) AND “28 U.S.C. § 1498”
`
`I-20
`
`I-21
`
`I-22
`
`I-23
`
`I-24 W58P05-22-C-0017 OR (*0017 W/2 contract)
`
`I-25 W911QY20C0100 OR (*0100 W/2 contract)
`
`I-26
`
`75A50120C00034 OR (*0034 W/2 contract)
`
`I-27
`
`I-28
`
`11,141,378 OR 11141378 OR 11,141,378* OR 11141378* OR ((pat OR pat* OR patent*)
`W/3 378) OR pat11141378*
`8,058,069 OR 8058069 OR 8,058,069* OR 8058069* OR ((pat OR pat* OR patent*) W/3
`069) OR pat8058069*
`8,492,359 OR 8492359 OR 8,492,359* OR 8492359* OR ((pat OR pat* OR patent*) W/3
`359) OR pat8492359*
`8,822,668 OR 8822668 OR 8,822,668* OR 8822668* OR ((pat OR pat* OR patent*) W/3
`668) OR pat8822668*
`9,364,435 OR 9364435 OR 9,364,435* OR 9364435* OR ((pat OR pat* OR patent*) W/3
`435) OR pat9364435*
`9,504,651 OR 9504651 OR 9,504,651* OR 9504651* OR ((pat OR pat* OR patent*) W/3
`651) OR pat9504651*
`II-01 W911QY20C0100 OR (*100 W/3 (contract OR agreement))
`
`I-29
`
`I-30
`
`I-31
`
`I-32
`
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`8 + AT +
`HB
`AT + HB
`
`2/28/2016 2/28/2022
`2/28/2012 2/28/2022
`
`2/28/2012 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`2/28/2016 2/28/2022
`
`12/1/2019
`
`present
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`
`Sharepoint
`N/A
`
`14,640
`4,676
`
`6,202
`
`683
`
`500
`
`4
`
`1,617
`
`8,436
`
`66
`
`209
`
`486
`
`214
`
`445
`
`101
`
`3,383
`
`

`

`Case 1:22-cv-00252-MSG Document 211-7 Filed 02/02/24 Page 3 of 4 PageID #: 14437
`
`Moderna's Search Terms, Sources, Dates, and Hits
`End Date Custodians Non-Custodial Hits + Fam.
`Moderna's Search Terms
`#
`Start Date
`present
`AT + HB
`N/A
`5,451
`II-02 W58P05-22-C-0017 OR (*17 W/3 (contract OR agreement))
`12/1/2019
`present
`AT + HB
`N/A
`8,673
`II-03
`(booster OR bivalent OR legacy OR prime) W/3 (agreement OR contract)
`12/1/2019
`present
`AT + HB
`N/A
`1,034
`II-04
`1498 W/30 (patent OR clause OR agreement OR contract)
`12/1/2019
`present
`AT + HB
`N/A
`1,764
`II-05
`52-227*
`12/1/2019
`present
`AT + HB
`N/A
`547
`II-06
`52227*
`12/1/2019
`II-07
`*hhs.gov
`12/1/2019 2/28/2022
`AT
`N/A
`1,317
`II-07.1
`*hhs.gov AND (mRNA-1273* OR (mRNA W/1 1273*) OR Spikevax* OR Elasomeran* OR
`COVID* OR lipid OR LNP OR Corbett OR BARDA OR stopwatch OR NIH
`
`
`12/1/2019 2/28/2022
`
`HB
`
`N/A
`
`32,045
`
`II-08
`II-09
`II-10
`II-11
`II-12
`III-01
`
`*army.mil
`*mail.mil
`"authorization and consent"
`patent indem*
`Section 1498
`(Emergency Use Authorization OR EUA OR ((BLA OR Biologics License) W/5 125752*)
`OR ((IND OR Investigational New Drug) W/5 19745*)) AND (((lipid* OR LNP*) W/5
`(molar* OR target* OR chang* OR approv* OR composit* OR formulat*)) OR ((chang*
`OR target* OR approv*) W/5 (PEG* OR ratio* OR ""##mol \u0025"" OR
`""##mol\u0025"" OR batch* OR encapsulat*)) OR patent*)
`
`12/1/2019
`12/1/2019
`12/1/2019
`12/1/2019
`12/1/2019
`
`present
`present
`present
`present
`present
`
`AT + HB
`AT + HB
`AT + HB
`AT + HB
`AT + HB
`
`N/A
`N/A
`N/A
`N/A
`N/A
`
`2,846
`7,518
`1,269
`990
`2
`
`12/1/2019 2/28/2022
`
`10
`
`Sharepoint
`
`17,953
`
`III-01.1 (Emergency Use Authorization OR EUA OR ((BLA OR Biologics License) W/5 125752*)
`OR ((IND OR Investigational New Drug) W/5 19745*)) AND (licens* OR sublicense* OR
`sub-licens* OR infring*)
`
`12/1/2019 2/28/2022
`
`10
`
`Sharepoint
`
`50,403
`
`III-02
`
`(PEG* OR DSPC OR cholesterol OR chol. OR chol OR phospholipid OR phos. OR phos OR
`cation* OR ioniz*) W/5 (ratio* OR molar OR content* OR concentra* OR conc. OR
`concs. OR conc OR "##mol\u0025")
`
`2/28/2012 2/28/2022
`
`10
`
`Sharepoint
`
`77,480
`
`III-03
`
`III-04
`
`III-05
`
`III-06
`
`III-07
`
`III-08
`
`III-09
`
`(mRNA-1273* OR (mRNA W/1 1273*) OR Spikevax* OR Elasomeran*) W/8 (ratio* OR
`molar OR lipid content* OR lipid conc* OR "##mol\u0025" OR patent* OR intellectual
`propert* OR IP OR licens* OR agreement OR sublicens* OR infring* OR entrap* OR
`encapsulat* OR sub-licens* OR Inex OR Protiva OR Genevant OR Tekmira OR Arbutus
`OR Acuitas OR AlCana OR Alnylam)
`
`12/1/2019 2/28/2022
`
`10
`
`Sharepoint
`
`34,813
`
`(mRNA* OR messenger RNA) W/5 (encapsulat* OR deliver*) AND (mRNA* OR
`messenger RNA) W/5 (challeng* OR difficul* OR hurdl* OR barrier OR barriers OR
`important* OR significan* OR key OR critical* OR overcom*)
`
` OR platform process) W/5 ((ratio* OR (lipid W/2
`molar) OR (lipid W/2 content) OR (lipid W/2 concentration) OR mol"##\u0025" OR
`encapsulat*))
`(*eop.gov OR *advancedvllc.com OR Advanced Decision Vectors OR *whitehouse.gov
`OR Operation Warp Speed OR OWS OR
`
`
`OR RxCrossroads) AND (mRNA-1273* OR (mRNA
`W/1 1273*) OR Spikevax* OR Elasomeran*)
`
`
`
`
`
`2/28/2016 2/28/2022
`
`10
`
`Sharepoint
`
`45,874
`
`1/1/2011
`
`2/28/2022
`
`10
`
`Sharepoint
`
`36,910
`
`2/28/2012 2/28/2022
`
`10
`
`Sharepoint
`
`225
`
`2/28/2016 2/28/2022
`
`10
`
`Sharepoint
`
`58,655
`
`SNALP* OR stable nucleic acid-lipid particle OR stable nucleic acid-lipid particles OR
`SPLP* OR stable plasmid lipid particle OR stable plasmid lipid particles
`
`1/1/2011
`
`2/28/2022
`
`10
`
`Sharepoint
`
`5,045
`
`(Mark W/2 Murray) OR (Ian W/2 MacLachlan) OR ((Antonin OR Tony) W/3
`Fougerolles))
`
`2/28/2016 2/28/2022
`
`10
`
`Sharepoint
`
`384
`
`

`

`Case 1:22-cv-00252-MSG Document 211-7 Filed 02/02/24 Page 4 of 4 PageID #: 14438
`
`#
`III-10
`
`
`
`
`
`Moderna's Search Terms, Sources, Dates, and Hits
`Moderna's Search Terms
`Start Date
`
`End Date Custodians Non-Custodial Hits + Fam.
`
`12/1/2019 2/28/2022
`
`10
`
`Sharepoint
`
`17,399
`
` TOTAL:
`
`308,911
`
`